The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC

Absztrakt
Leírás
Kulcsszavak
Forrás
Cancer Immunology Immunotherapy. -[Epub ahead of print] : - (2022), p. 1-18. -Cancer Immunol. Immunother. -0340-7004